Market Place
Sourcing Support
Amneal To Report First Quarter 2026 Results On May 1, 2026
07 Apr 2026 //
GLOBENEWSWIRE
Amneal To Participate In Upcoming Investor Conference
05 Mar 2026 //
GLOBENEWSWIRE
Amneal Reports Fourth Quarter & Full Year 2025 Financial Results
27 Feb 2026 //
GLOBENEWSWIRE
Amneal Pharmaceuticals Added To S&P Smallcap 600 Index
28 Jan 2026 //
GLOBENEWSWIRE
Amneal To Release Q4 And Full Year 2025 Results On Feb 27, 2026
27 Jan 2026 //
GLOBENEWSWIRE
Amneal And VantAI Unveil Fresh Branding To Kick Off 2026 Plans
14 Jan 2026 //
FIERCE PHARMA
Amneal To Participate In Upcoming Investor Conferences
02 Dec 2025 //
GLOBENEWSWIRE
Amneal Reports Third Quarter 2025 Financial Results
30 Oct 2025 //
GLOBENEWSWIRE
Amneal Launches Brekiya – the First and Only DHE Autoinjector
27 Oct 2025 //
GLOBENEWSWIRE
Amneal To Report Third Quarter 2025 Results On October 30, 2025
30 Sep 2025 //
GLOBENEWSWIRE
Amneal Reports Second Quarter 2025 Financial Results
05 Aug 2025 //
GLOBENEWSWIRE
Amneal Reveals Preliminary Q2 2025 Financial Results
21 Jul 2025 //
GLOBENEWSWIRE
Amneal Proposes Refinancing of Credit Agreement
21 Jul 2025 //
GLOBENEWSWIRE
Amneal`s Q2 2025 Results to be Reported on August 5
09 Jul 2025 //
GLOBENEWSWIRE
Amneal gets FDA approval for Prednisolone Acetate Ophthalmics
13 Jun 2025 //
GLOBENEWSWIRE
Amneal to Participate at Upcoming Investor Conferences in June
29 May 2025 //
GLOBENEWSWIRE
FDA approves Amneal`s self-administered migraine treatment
16 May 2025 //
REUTERS
Amneal and Apiject to Expand Sterile and BFS Capabilities in US
08 May 2025 //
GLOBENEWSWIRE
Amneal Reports First Quarter 2025 Financial Results
02 May 2025 //
BUSINESSWIRE
Amneal Donates $1.5 Million for Parkinson`s Awareness Month
11 Apr 2025 //
BUSINESSWIRE
Amneal to Report First Quarter 2025 Results on May 2, 2025
08 Apr 2025 //
BUSINESSWIRE
Amneal reveals Phase 3 data on CREXONT® in Parkinson’s Disease
07 Apr 2025 //
BUSINESSWIRE
Amneal expands Crexont® coverage for U.S. Parkinson`s patients
03 Apr 2025 //
BUSINESSWIRE
Amneal Launches Boruzu for Multiple Myeloma & Lymphoma
01 Apr 2025 //
BUSINESSWIRE
Amneal to Participate at Upcoming Investor Conference
10 Mar 2025 //
BUSINESSWIRE
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
28 Feb 2025 //
BUSINESSWIRE
Amneal to Report Q4 & Full Year 2024 Results on Feb 28
29 Jan 2025 //
BUSINESSWIRE
Amneal Gets FDA Nod For Memantine/Donepezil & Everolimus
23 Jan 2025 //
BUSINESSWIRE
Amneal to Participate at Upcoming Investor Conferences
04 Dec 2024 //
BUSINESSWIRE
Amneal Reports Q3 2024 Financial Results
08 Nov 2024 //
BUSINESSWIRE
Amneal Receives FDA Approval For Pyridostigmine Bromide Tablets
21 Oct 2024 //
BUSINESSWIRE
Amneal to Report Third Quarter 2024 Results on November 8, 2024
08 Oct 2024 //
BUSINESSWIRE
Amneal And Metsera Partner On Next-Gen Obesity Medicines
01 Oct 2024 //
BUSINESSWIRE
Amneal Launches CREXONT For Parkinson`s Disease Treatment
23 Sep 2024 //
BUSINESSWIRE
Amneal and Shilpa Announce FDA Approval Of BORUZU, Ready-to-Use
05 Sep 2024 //
BUSINESSWIRE
Amneal Gets FDA Approval For Propofol Injectable Emulsion Single Dose Vials
20 Aug 2024 //
BUSINESSWIRE
Amneal Reports Second Quarter 2024 Financial Results
09 Aug 2024 //
BUSINESSWIRE
Amneal Receives FDA Approval For CREXONT To Treat Parkinson`s Disease
07 Aug 2024 //
BUSINESSWIRE
Amneal Clinches Approval For Extended-Release Parkinson`s Med
07 Aug 2024 //
FIERCE PHARMA
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
29 Jul 2024 //
BUSINESSWIRE
Amneal to Report Second Quarter 2024 Results on August 9, 2024
11 Jul 2024 //
BUSINESSWIRE
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
09 Jul 2024 //
BUSINESSWIRE
Amneal Releases 2023 Environmental, Social and Governance Report
28 Jun 2024 //
BUSINESSWIRE
Amneal: Expands Injectables Portfolio To Over 40 Products
05 Jun 2024 //
BUSINESSWIRE
Amneal Launches OTC Naloxone In US Retail, California
22 May 2024 //
BUSINESSWIRE
Amneal to Participate at Upcoming Investor Conference
22 May 2024 //
BUSINESSWIRE
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
04 May 2024 //
REUTERS
Amneal Reports First Quarter 2024 Financial Results
03 May 2024 //
BUSINESSWIRE
Amneal`s OTC Naloxone Nasal Spray Approved
24 Apr 2024 //
BUSINESSWIRE
Amneal appoints Sandeep Raktate as President -Operations, India & Ireland
19 Apr 2024 //
EXPRESSPHARMA
Shilpa Medicare launches Pemetrexed injection
19 Apr 2024 //
INDINPHARMAPOST
Amneal Launches PEMRYDI RTU® Oncology Injectable Ready-To-Use
16 Apr 2024 //
BUSINESSWIRE
Amneal to Report First Quarter 2024 Results on May 3, 2024
10 Apr 2024 //
BUSINESSWIRE
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
28 Mar 2024 //
BUSINESSWIRE
Amneal Receives FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
25 Mar 2024 //
BUSINESSWIRE
Amneal to Participate at Upcoming Investor Conference
13 Feb 2024 //
BUSINESSWIRE
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
31 Jan 2024 //
BUSINESSWIRE
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023
04 Jan 2024 //
BUSINESSWIRE
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
BUSINESSWIRE
GSK, Amneal and Kaleo walk back patents after FTC`s challenge
21 Dec 2023 //
FIERCE PHARMA
